Type
|
Public (NYSE: MR) |
---|---|
Industry | Medical Devices |
Founded | Shenzhen, China (1991) |
Headquarters | Shenzhen, China |
Key people
|
President & Co-CEO LI Xiting, Co-CEO CHENG Minghe |
Products | Patient Monitors, ECG, Pulse Oxymeters, Telemetery, Ultrasound Systems, Anesthesia Delivery Systems, Hematology Analyzers, Chemistry Analyzers, Regents, Veterinary Equipment |
Revenue | $1.3 billion USD (2014) |
Net income
|
$193 million |
Number of employees
|
about 10,000 (2014) |
Website | Mindray Datascope Patient Monitors |
Footnotes / references U.S. Food and Drug Administration registration numbers 3007222337, 3004365718, and 2221819 |
Mindray Medical International Limited is China's largest medical equipment manufacturer, developing, manufacturing, and marketing a variety of medical devices, equipment and accessories for both human and veterinary use. The company is currently organized into three key business lines: Patient Monitoring & Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems.
Headquartered in Shenzhen, China, Mindray possesses a sound R&D, marketing and service network with 41 subsidiaries and branch offices in 31 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 32 branch offices in China. To date, Mindray has around 8200 employees around the world. Its North American headquarters are located in Mahwah, New Jersey.
The Patient Monitoring & Life Support division develops and manufactures multi-parameter patient monitors, biotelemetry systems, Anesthesia Delivery Systems, Defibrillators, ECG machines, pulse oxymeters, hospital beds, mounting systems and IT solutions for customers worldwide. In 2008, Mindray purchased the Patient Monitoring division of Datascope Corporation for $209 million to expand their presence outside of China.
The In-Vitro Diagnostic division provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment. This segment offers a range of semi-automated and fully automated diagnostic laboratory instruments for laboratories, clinics, and hospitals. Its products include hematology analyzers, biochemistry analyzers, reagents, a microplate reader and a microplate washer.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2020 | 2020-11-05 | 0.00 | 0.00 |
Q2 2020 | 2020-08-06 | -0.57 | -1.88 |
Q1 2020 | 2020-05-07 | 0.03 | 0.30 |
Q4 2019 | 2020-03-05 | 0.89 | 0.39 |
Q3 2019 | 2019-11-07 | 0.54 | 0.15 |
Q2 2019 | 2019-08-06 | 0.41 | 0.69 |
Q1 2019 | 2019-05-07 | 0.70 | -0.54 |
Q4 2018 | 2019-03-12 | 1.16 | 1.80 |
Q3 2018 | 2018-10-31 | 0.60 | 0.15 |
2015-11-13 | Reiterated Rating | Standpoint Research | Buy to Hold | |
2015-10-23 | Downgrade | Deutsche Bank | Buy to Hold | $30.00 to $27.00 |
2015-10-23 | Downgrade | Deutsche Bank AG | Buy to Hold | $30.00 to $27.00 |
2015-06-05 | Upgrade | JMP Securities | Underperform to Market Perform | $30.00 |
2015-05-22 | Reiterated Rating | JMP Securities | Underperform | $22.00 to $20.00 |
2015-03-11 | Lower Price Target | JMP Securities | Market Underperform | $23.00 to $22.00 |
2015-03-11 | Downgrade | Credit Suisse | Neutral to Underperform | |
2015-03-11 | Downgrade | Credit Suisse Group AG | Neutral to Underperform | |
2015-03-06 | Set Price Target | Deutsche Bank | Buy | $34.00 |
2014-12-22 | Initiated Coverage | Standpoint Research | Buy | $36.00 |
2014-12-12 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $37.00 to $28.00 |
2014-05-22 | Lower Price Target | Jefferies Group | Hold | $36.00 to $32.00 |
2014-05-07 | Downgrade | Bank of America | Buy to Neutral | |
2014-05-06 | Reiterated Rating | Morgan Stanley | In-Line | |
2014-04-24 | Upgrade | Credit Suisse | Underperform to Neutral | |
2014-04-14 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $44.00 to $37.00 |
2014-04-07 | Downgrade | Goldman Sachs | Buy to Neutral | $45.50 to $31.20 |
2014-03-04 | Lower Price Target | Oppenheimer | Outperform | $50.00 to $42.00 |
2013-12-13 | Upgrade | Bank of America | Buy | |
2013-11-06 | Lower Price Target | Jefferies Group | Hold | $43.00 to $36.00 |
2013-11-04 | Initiated Coverage | Credit Suisse | Underperform | |
2010-08-11 | Downgrade | Brean Murray | Buy to Hold | |
2009-12-11 | Initiated | Citigroup | Buy | $36 |
2009-08-25 | Initiated | Soleil | Buy | |
2009-07-27 | Initiated | Susquehanna Financial | Positive | |
2008-12-18 | Initiated | Maxim Group | Buy | $35 |
2008-12-02 | Reiterated | Credit Suisse | Outperform | $41 to $36 |
2008-02-21 | Initiated | Citigroup | Buy | |
2007-11-21 | Initiated | Bear Stearns | Outperform | |
2007-11-12 | Upgrade | UBS | Neutral to Buy | |
2007-11-02 | Reiterated | Brean Murray | Buy | $39 to $50 |
2007-08-07 | Reiterated | Brean Murray | Buy | $36 to $39 |
2015-11-13 | Reiterated Rating | Standpoint Research | Buy to Hold | |
2015-10-23 | Downgrade | Deutsche Bank | Buy to Hold | $30.00 to $27.00 |
2015-10-23 | Downgrade | Deutsche Bank AG | Buy to Hold | $30.00 to $27.00 |
2015-06-05 | Upgrade | JMP Securities | Underperform to Market Perform | $30.00 |
2015-05-22 | Reiterated Rating | JMP Securities | Underperform | $22.00 to $20.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In MR 5 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
MANAGED ACCOUNT ADVISORS LLC | 0.22M |
Farmstead Capital Management, LLC | 0.12M |
TIAA CREF INVESTMENT MANAGEMENT LLC | 19136 |
TEACHERS ADVISORS INC | 14876 |
Index Management Solutions, LLC | 479 |